SNBL at ACT2019

SNBL will be exhibiting at the American College of Toxicology from November 17 to 20, 2019. If you are at ACT please pop by Booth #103 and let's chat about how we can support your drug development program. 


SNBL to be represented by Medgaea Life Sciences, Ltd. in Taiwan

SNBL and Medgaea Life Sciences, Ltd. (MDG) have signed an agreement for Medgaea Life Sciences to represent SNBL in Taiwan.


The pharmaceutical industry is growing in Taiwan with government support, concentrated around biopharmaceuticals. With its close location and commitment to quality, SNBL is a great choice for preclinical contract research for Taiwanese organizations.


MDG was established in Taiwan in 2005 and offers a variety of preclinical contract research services for medical devices, health foods, pharmaceuticals, and herbal remedies. SNBL and MDG have an excellent cooperative relationship.


The partnership between SNBL and MDG will offer an abundance of support for R&D of pharmaceuticals, medical devices, and regenerative medicine in Taiwan.



Presenting at the Safety Pharmacology Society in Barcelona

At the Safety Pharmacology Society 2019, held in Barcelona from September 23-26, Tsuyoshi Uchino, who is one of SNBL's safety pharmacology experts will present a poster entitled "Utility of Heart Rate Variability Analysis in Telemeterized Cynomolgus Monkeys" on September 24 and 25. 


If you are attending SPS, please visit Tsuyoshi at Poster #134.


Otherwise please email if you are interested in obtaining a copy of the poster.

Gemseki chosen as Top 10 by magazine

Gemseki, a member of SNBL group, was chosen as one of the top 10 drug discovery service companies in APAC by Pharma Tech Outlook, and is the cover story for the the Safety Pharmacology Society 2019.


See a PDF link to the media release here.



Meet SNBL at Eurotox 2019





SNBL will be exhibiting at the 55th Eurotox Congress from 8 - 11 September in Helsinki, Finland.


Drop by Booth #61 or email to see how SNBL can provide preclinical support for your drug development program.